Rhumbline Advisers lowered its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 4.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 67,891 shares of the medical instruments supplier's stock after selling 3,287 shares during the period. Rhumbline Advisers owned 0.28% of ICU Medical worth $10,535,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in ICUI. Creative Planning boosted its holdings in ICU Medical by 58.6% in the third quarter. Creative Planning now owns 6,193 shares of the medical instruments supplier's stock worth $1,128,000 after acquiring an additional 2,287 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of ICU Medical during the third quarter valued at $442,000. Greenleaf Trust purchased a new stake in shares of ICU Medical in the 3rd quarter worth approximately $207,000. Allworth Financial LP lifted its position in ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier's stock valued at $36,000 after acquiring an additional 100 shares during the last quarter. Finally, Louisiana State Employees Retirement System grew its position in ICU Medical by 14.6% during the 3rd quarter. Louisiana State Employees Retirement System now owns 11,800 shares of the medical instruments supplier's stock worth $2,150,000 after purchasing an additional 1,500 shares during the last quarter. 96.10% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages have issued reports on ICUI. KeyCorp upped their target price on ICU Medical from $198.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, November 13th. Needham & Company LLC reiterated a "hold" rating on shares of ICU Medical in a report on Wednesday, November 13th. StockNews.com upgraded ICU Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, November 20th. Finally, Jefferies Financial Group upgraded shares of ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 price objective on the stock in a research note on Wednesday, December 11th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, ICU Medical presently has a consensus rating of "Moderate Buy" and an average price target of $199.67.
Check Out Our Latest Analysis on ICUI
Insider Activity at ICU Medical
In related news, CEO Vivek Jain sold 1,373 shares of the firm's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the transaction, the chief executive officer now directly owns 104,593 shares of the company's stock, valued at $16,262,119.64. This trade represents a 1.30 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 6.70% of the stock is currently owned by insiders.
ICU Medical Price Performance
Shares of ICUI stock traded down $4.52 during trading hours on Thursday, reaching $149.75. 388,345 shares of the company were exchanged, compared to its average volume of 201,601. ICU Medical, Inc. has a fifty-two week low of $93.36 and a fifty-two week high of $196.26. The stock's fifty day moving average is $160.70 and its two-hundred day moving average is $166.21. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The company has a market cap of $3.67 billion, a price-to-earnings ratio of -32.77 and a beta of 0.63.
ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.48 by $0.24. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.05%. Sell-side analysts forecast that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.
About ICU Medical
(
Free Report)
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
See Also
Before you consider ICU Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ICU Medical wasn't on the list.
While ICU Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
